

Datasheet: MCA1784F BATCH NUMBER 154597

| Description: | RAT ANTI HUMAN EGF RECEPTOR:FITC |
|---------------|----------------------------------|
| Specificity: | EGF R |
| Other names: | EPIDERMAL GROWTH FACTOR RECEPTOR |
| Format: | FITC |
| Product Type: | Monoclonal Antibody |
| Clone: | ICR10 |
| Isotype: | lgG2a |
| Quantity: | 0.1 mg |

Product Details

| Applications | This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> . | | | | |
|-----------------------------------|--|---------------------|--|------------------------|--|
| | | Yes No | Not Determined | Suggested Dilution | |
| | Flow Cytometry | | | 1/10 | |
| | necessarily exclude its | use in such procede | or use in a particular tec ures. It is recommended ing appropriate negativ | that the user titrates | |
| Target Species | Human | | | | |
| Product Form | Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid | | | | |
| Max Ex/Em | Fluorophore | Excitation Max (nm) | • • | | |
| | FITC | 490 | 525 | | |
| Preparation | Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant | | | | |
| Buffer Solution | Phosphate buffered saline | | | | |
| Preservative | 0.09% Sodium Azide | | | | |
| Stabilisers | 1% Bovine Serum A | Albumin | | | |
| Approx. Protein Concentrations | IgG concentration 0.1 | mg/ml | | | |

| Immunogen | Extracellular domain of human EGF-receptor from head and neck carcinoma. |
|----------------------------|--|
| External Database Links | UniProt: <u>P00533</u> <u>Related reagents</u> Entrez Gene: <u>1956</u> EGFR <u>Related reagents</u> |
| Synonyms | ERBB1 |
| RRID | AB_324284 |
| Specificity | Rat anti Human EGF Receptor antibody, clone ICR10 recognizes the human epidermal growth factor receptor (EGF-R), which is over expressed in a high proportion of breast cancer cells and in a range of other carcinomas. |
| | High level expression of EGFR is often associated with advanced disease and poor prognosis. |
| | Rat anti Human EGF Receptor antibody, clone ICR10 binds to epitope B from EGFR (<u>Lottaz <i>et al.</i> 2010</u> and <u>Moditahedi <i>et al.</i> 1993</u>) and has an affinity of 6.7 x 10^{-9} M. |
| Flow Cytometry | Use 10ul of the suggested working dilution to label 10^6 cells in 100ul. |
| References | Lottaz, C. <i>et al.</i> (2010) Transcriptional Profiles of CD133+ and CD133- Glioblastoma- Derived Cancer Stem Cell Lines Suggest Different Cells of Origin <u>Cancer Res. 70:</u> <u>2030-40.</u> Modjtahedi, H. <i>et al.</i> (1993) Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. <u>Cell</u> <u>Biophys. 22 (1-3): 129-46.</u> Modjtahedi, H. <i>et al.</i> (2012) Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. <u>Br J</u> <u>Cancer. 106 (5): 883-8.</u> Grinberg, O. <i>et al.</i> (2013) Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine <u>Polymers for Advanced Technologies.</u> <u>24 (3): 294-299.</u> Gilcrease, M.Z. <i>et al.</i> (2009) Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J Exp Clin Cancer Res. 28: <u>67.</u> Tilburgs, T. <i>et al.</i> (2015) Human HLA-G+ extravillous trophoblasts: Immune-activating cells that interact with decidual leukocytes. <u>Proc Natl Acad Sci U S A. 112 (23): 7219-24.</u> Tilburgs, T. <i>et al.</i> (2015) The HLA-G cycle provides for both NK tolerance and immunity at the maternal-fetal interface. <u>Proc Natl Acad Sci U S A. 112 (43): 13312-7.</u> Khelwatty, S.A. <i>et al.</i> (2015) Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. <u>Br J Cancer. 113 (7): 1010-9.</u> |

| Storage | This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C. | | |
|----------------------------------|---|-----|--|
| | Avoid repeated freezing and thawing as this may denature the frost-free freezers is not recommended. This product is photose protected from light. | , , | |
| Guarantee | 12 months from date of despatch | | |
| Health And Safety Information | Material Safety Datasheet documentation #10041 available at: https://www.bio-rad-antibodies.com/SDS/MCA1784F 10041 | | |
| Regulatory | For research purposes only | | |

Related Products

Recommended Negative Controls

RAT IgG2a NEGATIVE CONTROL:FITC (MCA6005F)

Recommended Useful Reagents

HUMAN SEROBLOCK (BUF070A) HUMAN SEROBLOCK (BUF070B)

 North & South
 Tel: +1 800 265 7376
 Worldwide

 America
 Fax: +1 919 878 3751
 Email: antibody_sales_us@bio-rad.com

Tel: +44 (0)1865 852 700 **Europe** Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M395619:220519'

Printed on 22 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint